Heron Therapeutics, Inc. (HRTX) vs RenovoRx, Inc. (RNXT)
A side-by-side comparison of Heron Therapeutics, Inc. and RenovoRx, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HRTX
Heron Therapeutics, Inc.
$0.34HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
RNXT
RenovoRx, Inc.
$1.43HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
Total return — HRTX vs RNXT
growth of $100 · dividends reinvested · last 5yHRTX -96.8% (-49.7%/yr)RNXT -79.8% (-27.3%/yr)RNXT compounded faster over this window
Log scale — wide-divergence pair
HRTX RNXT
HRTX vs RNXT: by the numbers
- •HRTX is the larger company ($65M vs $64M market cap).
- •Both run net losses; HRTX's is the smaller (-22.52% vs -621.71% net margin).
Metrics side by side
Valuation
| Metric | HRTX | RNXT |
|---|---|---|
| P/S ratio | 0.43 | 32.60 |
| P/B ratio | 11.05 | 7.18 |
Profitability
| Metric | HRTX | RNXT |
|---|---|---|
| Gross margin | 70.07% | 70.88% |
| Operating margin | -7.19% | -1113.98% |
| Net margin | -22.52% | -621.71% |
| ROE | -492.89% | -136.82% |
| ROIC | -6.79% | -139.74% |
Growth (annualized)
| Metric | HRTX | RNXT |
|---|---|---|
| Revenue CAGR (5Y) | 12.73% | N/A |
| Total return CAGR (5Y) | -48.61% | -23.80% |
Frequently asked
- How have HRTX and RNXT total returns compared?
- Over the past 5 years, HRTX delivered -48.61% and RNXT delivered -23.80% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.